Genmab A/S
FSX: GE9.F0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Frankfurt Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Jan van de Winkel
- Employees
- 2,638
- Headquarters
- Copenhagen, Denmark
- IPO year
- 2000
- Market cap
- €13.6B
- Website
- https://www.genmab.com
Loading GE9…
Loading profile data…Frequently asked questions about GE9
What does Genmab A/S (GE9.F) do?
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal...
Where does GE9.F trade?
Genmab A/S (GE9.F) trades on the Frankfurt Stock Exchange.
What sector is GE9.F in?
Genmab A/S (GE9.F) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Genmab A/S?
Jan van de Winkel is the chief executive officer of Genmab A/S (GE9.F).
Where is Genmab A/S headquartered?
Genmab A/S is headquartered in Denmark.
Does GE9.F pay a dividend?
Genmab A/S (GE9.F) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GE9.F go public?
Genmab A/S (GE9.F) completed its initial public offering in 2000.